세계의 3D 세포배양 시장 : 제품별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

The global 3D cell culture market is projected to reach USD 2.26 billion by 2030 from USD 1.18 billion in 2024, at a CAGR of 11.7% during the forecast period.

Factors such as increased adoption of 3D cell culture and a rise in funding for 3D cell culture research drive market growth.

The scaffold-based 3D cell culture segment accounted for the highest market share in the product market.

Based on the product, the 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. The scaffold-based 3D cell cultures segment accounted for the largest share in 2024. Hydrogels/ECM analogs have emerged as the key contributor to segment growth. Increased demand for hydrogels is raising the focus of key market players on the development and launch of new products in the market. It is also biocompatible and non-toxic, making it ideal for use in research and drug development.

The cancer and stem cell research segment accounted for the largest share of the application market in 2024.

Based on the application, the market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. Cancer & stem cell segment research accounted for the largest market share in 2024. The increasing prevalence of cancer and significant funding initiatives for cancer research from the government and the private sector are major factors driving the growth of this application segment.

The Asia Pacific region is likely to be the fastest-growing regional market.

The 3D cell culture market is segmented into Europe, Asia Pacific, North America, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to be the fastest-growing regional segment during the forecast period. Growth in this market is attributed to the presence of favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian countries. The markets for biologics such as antibodies and protein-based drugs are also on the rise in the Asia Pacific region. Biotechnology-based drugs are anticipated to be one of the key drivers for the research industry due to increased research and government funds provided for these drugs. Global pharmaceutical firms are increasingly moving to Asia to tap into its thriving market and lower their production costs by shifting manufacturing to the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1- 25%, Tier 2- 35%, and Tier 3- 40%
• By Designation: C-level Executives- 55%, Directors- 20%, and Others- 25%
• By Region: North America- 45%, Europe- 20%, the Asia Pacific- 20%, Latin America- 10%, the Middle East- 3%, and Africa- 2%

The top players in the global 3D cell culture market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Tecan Trading AG (Switzerland), Avantor, REPROCELL Inc. (Japan), 3D Biotek LLC. (US), S-BIO, Vaupell Holdings Inc. (US), Advanced BioMatrix Inc. (US), UPM Biomedicals (Finland), SYNTHECON, INCORPORATED (US), Emulate, Inc. (US), CN Bio Innovations Ltd. (UK), Kirkstall Ltd. (UK), Lena Biosciences (US), TissUse GmbH (Germany), Cellendes GmbH (Germany), Greiner Bio-one International GmbH (Germany), AMSBIO (UK), MIMETAS B.V.(Netherlands), and Promocell GmbH (Germany).

Research Coverage

This research report categorizes the 3D cell culture market by product (scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures), application (cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine), end user (pharmaceutical & biotechnology companies, research institutes, cosmetics industry, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the 3D cell culture market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the 3D cell culture market. This report covers a competitive analysis of top players and upcoming startups in the 3D cell culture market ecosystem.

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the 3D cell culture market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product launches, acquisitions, and recent developments associated with the 3D cell culture market. This report covers the competitive analysis of upcoming startups in the 3D cell culture market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall 3D cell culture market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (high focus on developing alternatives to animal testing, increasing adoption of personalized medicine, increased government support and funding, rising academia-research collaborations), restraints (high cost of implementing 3D cell culture technologies, lack of widely accepted or single standardization in 3D cell culture), opportunities (emergence of microfluidic based 3D cell culture), and challenges (lack of consistency in 3D cell culture products, high dependency on plastic waste disposals and consumables) influencing the growth of 3D cell culture market.
• Product Development/Innovation: Detailed insights on newly launched products of the 3D cell culture market
• Market Development: Comprehensive information about lucrative markets - the report analyses the 3D cell culture market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the 3D cell culture market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), and Avantor Inc. (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF STRATEGIC CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET SIZE ESTIMATION
    • 2.2.1.1 Revenue share analysis (bottom-up approach)
    • 2.2.1.2 Secondary data
    • 2.2.1.3 Primary interviews and MnM repository analysis
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
• 2.3 GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
• 3.3 DISRUPTIVE TRENDS SHAPING MARKET
• 3.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
• 3.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS

• 4.1 UNMET NEEDS AND WHITE SPACES
• 4.2 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.3 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
• 4.4 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
• 4.5 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
• 4.6 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 High focus on developing alternatives to animal testing
    • 5.2.1.2 Growing shift toward personalized medicine
    • 5.2.1.3 Integration of microphysiological systems and organ-on-chip platforms
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of implementing 3D cell culture technologies
    • 5.2.2.2 Absence of widely accepted or unified standards for experimental protocols
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth opportunities and booming biopharmaceutical sector in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of consistency in scaffold-based 3D cell culture products
    • 5.2.4.2 High dependence on plastic waste disposals and consumables
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Microfluidics
    • 5.3.1.2 Bioprinting
    • 5.3.1.3 Organ-on-chip
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 High-content imaging and automated microscopy
    • 5.3.2.2 High-throughput screening platforms
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Magnetic levitation
    • 5.3.3.2 Microfabrication
• 5.4 TRADE ANALYSIS
  • 5.4.1 IMPORT DATA
  • 5.4.2 EXPORT DATA
• 5.5 REGULATORY LANDSCAPE
  • 5.5.1 REGULATORY FRAMEWORK
    • 5.5.1.1 North America
    • 5.5.1.2 Europe
    • 5.5.1.3 Asia Pacific
    • 5.5.1.4 Latin America
    • 5.5.1.5 Middle East & Africa
  • 5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 BARGAINING POWER OF SUPPLIERS
  • 5.6.2 BARGAINING POWER OF BUYERS
  • 5.6.3 THREAT OF NEW ENTRANTS
  • 5.6.4 THREAT OF SUBSTITUTES
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 IMPACT OF AI/GENERATIVE AI ON 3D CELL CULTURE MARKET
  • 5.7.1 INTRODUCTION
  • 5.7.2 MARKET POTENTIAL OF AI IN 3D CELL CULTURE APPLICATIONS
  • 5.7.3 AI USE CASES
  • 5.7.4 KEY COMPANIES IMPLEMENTING AI
  • 5.7.5 FUTURE OF GENERATIVE AI IN 3D CELL CULTURE ECOSYSTEM
• 5.8 IMPACT OF 2025 US TARIFF ON 3D CELL CULTURE MARKET
  • 5.8.1 INTRODUCTION
  • 5.8.2 KEY TARIFF RATES
  • 5.8.3 PRICE IMPACT ANALYSIS
  • 5.8.4 IMPACT ON COUNTRY/REGION
    • 5.8.4.1 US
    • 5.8.4.2 Europe
    • 5.8.4.3 Asia Pacific
  • 5.8.5 IMPACT ON END-USE INDUSTRIES
    • 5.8.5.1 Pharmaceutical and biotech companies
    • 5.8.5.2 Hospitals and diagnostic laboratories
    • 5.8.5.3 Academic and research institutes
    • 5.8.5.4 Contract research organizations & contract development and manufacturing organizations

6 INDUSTRY TRENDS

• 6.1 PRICING ANALYSIS
  • 6.1.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 6.1.2 AVERAGE SELLING PRICE TREND, BY REGION
• 6.2 PATENT ANALYSIS
  • 6.2.1 METHODOLOGY
  • 6.2.2 NUMBER OF PATENTS FILED
  • 6.2.3 LIST OF KEY PATENTS
• 6.3 KEY CONFERENCES AND EVENTS, 2025-2026
• 6.4 INVESTMENT AND FUNDING SCENARIO
• 6.5 VALUE CHAIN ANALYSIS
• 6.6 ECOSYSTEM ANALYSIS
• 6.7 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 6.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 6.7.2 KEY BUYING CRITERIA
• 6.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

7 3D CELL CULTURE MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 SCAFFOLD-BASED 3D CELL CULTURES
  • 7.2.1 HYDROGELS/ECM ANALOGS
    • 7.2.1.1 Hydrogels/ECM analogs to dominate scaffold-based 3D cell culture market during forecast period
  • 7.2.2 SOLID SCAFFOLDS
    • 7.2.2.1 Growing adoption of solid scaffolds in regenerative medicine and preclinical in vitro testing to boost market
  • 7.2.3 MICROPATTERNED SURFACES
    • 7.2.3.1 Ability of micropatterned surfaces to enhance expression of enzyme levels and drug reactivity to drive growth
• 7.3 SCAFFOLD-FREE 3D CELL CULTURES
  • 7.3.1 LOW-ATTACHMENT PLATES
    • 7.3.1.1 Low-attachment plates to grow at highest rate in scaffold-free 3D cell cultures market
  • 7.3.2 HANGING DROP PLATES
    • 7.3.2.1 Growing use of hanging drop plates in stem cell differentiation and cytotoxicity research to propel growth
  • 7.3.3 3D BIOREACTORS
    • 7.3.3.1 Wide usage of 3D bioreactors in mass production of cells to support market growth
• 7.4 MICROFLUIDICS-BASED 3D CELL CULTURES
  • 7.4.1 MICROFLUIDICS-BASED 3D CELL CULTURES TO GROW AT HIGHEST RATE IN 3D CELL CULTURE MARKET DURING FORECAST PERIOD
• 7.5 MAGNETIC & BIOPRINTED 3D CELL CULTURES
  • 7.5.1 GROWING USE OF BIOPRINTING TECHNOLOGIES IN CANCER MODEL CREATION TO BOOST MARKET

8 3D CELL CULTURE MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 CANCER & STEM CELL RESEARCH
  • 8.2.1 INCREASING DEMAND FOR PATIENT-DERIVED, AUTOMATED 3D ORGANOID SYSTEMS TO PROPEL MARKET
• 8.3 DRUG DISCOVERY & TOXICOLOGY TESTING
  • 8.3.1 REGULATORY DEMAND AND TECHNOLOGICAL MATURATION OF PREDICTIVE 3D TOXICOLOGY MODELS TO DRIVE MARKET GROWTH
• 8.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE
  • 8.4.1 ADVANCEMENTS IN BIOMATERIAL INNOVATION AND SCAFFOLD CUSTOMIZATION TO BOOST MARKET
• 8.5 3D CELL CULTURE MARKET, BY MODEL TYPE

9 3D CELL CULTURE MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 GROWING INTEGRATION OF 3D MODELS BY PHARMA AND BIOTECH COMPANIES TO DRIVE MARKET GROWTH
• 9.3 RESEARCH INSTITUTES
  • 9.3.1 RESEARCH GRANTS FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS TO AUGMENT MARKET
• 9.4 COSMETICS INDUSTRY
  • 9.4.1 GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR ANIMAL TESTING TO FUEL MARKET
• 9.5 OTHER END USERS

10 3D CELL CULTURE MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Product launches and capacity expansions to drive market growth
  • 10.2.3 CANADA
    • 10.2.3.1 Advancements in tissue therapeutics and regenerative medicine to boost market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Strategic acquisitions to fuel market growth
  • 10.3.3 UK
    • 10.3.3.1 Growing government funding and initiatives to propel market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Strategic collaborations to propel market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Strong government support to enhance R&D activities
  • 10.3.6 SPAIN
    • 10.3.6.1 Strategic R&D investments and collaborative frameworks to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Rising pharmaceutical R&D and investments to drive market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Strategic collaborations and technological advancements to augment market
  • 10.4.4 INDIA
    • 10.4.4.1 Strategic collaborations and infrastructure development to support market
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Strategic investments and collaborations to propel market growth
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 Advancements in 3D cell culture technologies to propel market
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Rising prevalence of cancer and therapeutic development to support market
  • 10.5.3 MEXICO
    • 10.5.3.1 Growth in biopharmaceutical market to spur 3D cell culture demand
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Saudi Arabia
      • 10.6.2.1.1 Strategic healthcare initiatives to drive market
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Developments in healthcare infrastructure and growing government initiatives to drive market
    • 10.6.2.3 Rest of GCC Countries
  • 10.6.3 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 STRATEGIC COLLABORATIONS AND HEALTH INITIATIVES TO FUEL MARKET GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN 3D CELL CULTURE MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.5.1 COMPANY VALUATION
  • 11.5.2 FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Product footprint
    • 11.7.5.4 Application footprint
    • 11.7.5.5 End-user footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.8.5.1 Detailed list of key startups/SMEs
    • 11.8.5.2 Competitive benchmarking of startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 THERMO FISHER SCIENTIFIC INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 MERCK KGAA
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
      • 12.1.2.3.2 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 CORNING INCORPORATED
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 LONZA
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 AVANTOR, INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
  • 12.1.6 TECAN TRADING AG
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 MnM view
      • 12.1.6.3.1 Key strengths
      • 12.1.6.3.2 Strategic choices
      • 12.1.6.3.3 Weaknesses and competitive threats
  • 12.1.7 REPROCELL INC.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 3D BIOTEK LLC
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 EMULATE, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
  • 12.1.10 SYNTHECON, INCORPORATED
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 INSPHERO
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Other developments
  • 12.1.12 KIRKSTALL LTD.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 GREINER BIO-ONE INTERNATIONAL GMBH
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 PROMOCELL GMBH
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 UPM
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 CN BIO INNOVATIONS LTD.
  • 12.2.2 TISSUSE GMBH
  • 12.2.3 LENA BIOSCIENCES
  • 12.2.4 CELLENDES GMBH
  • 12.2.5 ADVANCED BIOMATRIX, INC. (PART OF BICO)
  • 12.2.6 SYNVIVO, INC.
  • 12.2.7 AMS BIOTECHNOLOGY (EUROPE) LTD
  • 12.2.8 MIMETAS B.V.
  • 12.2.9 S-BIO, VAUPELL HOLDINGS INC.
  • 12.2.10 NANOFIBER SOLUTIONS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS